Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. https://t.co/8zLB9cYX0d
RT @JNeurooncol: Na et al. report the utility of the TruSight Tumor 170 panel-based Next Generation Sequencing (NGS) assay for genotyping d…
Not sure how clinically useful this is. Potentially targetable mutations/ fusions not included. What say you #btsm?
RT @JNeurooncol: Na et al. report the utility of the TruSight Tumor 170 panel-based Next Generation Sequencing (NGS) assay for genotyping d…
RT @JNeurooncol: Na et al. report the utility of the TruSight Tumor 170 panel-based Next Generation Sequencing (NGS) assay for genotyping d…
Na et al. report the utility of the TruSight Tumor 170 panel-based Next Generation Sequencing (NGS) assay for genotyping diffuse gliomas, which may improve diagnostic accuracy of these tumors. The figure compares the deletions identified by FISH and NGS. h
@mlage @CraigHorbinski @DrTomJacques @neuropathobern @kriyer68 #newupdatesneuroonc #IDH #neuropath #gliomas Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. - https://t.co/t2h
#newupdatesneuroonc #braintumours #neuroonc Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases - https://t.co/ZNKvoCJ5jJ